

PROTECTOR is supported by Barts and the London Charity and The Rosetrees Trust

## **PROTECTOR Newsletter – February 2024**

## Welcome to the PROTECTOR newsletter!

We have now recruited over 1150 patients to the study and would like to thank all those involved to date. Total recruitment currently stands at **1191 patients.** PROTECTOR is now active at **42 sites**.

- PROTECTOR is registered with the **NIHR Associate PI Scheme.** Congratulations to **Kathryn Baxter** and **Nazish Zulfiqar** for recently completing this! Information about the scheme is in the attached presentation, please consider signing up!
- Thank you to the teams in **Sandwell, ELHT and Portsmouth** who have performed very well recently! Treats are on their way to all of you!
- Thank you to all sites and pathologists for your patience while the database is down. We apologise for the
  inconvenience caused. Our IT team is working hard to address this, and we will let you know as soon as this gets
  sorted. As per the contingency SOP, please continue emailing protector.study@nhs.net to obtain VRN allocations for
  new patients and <u>bci-protector@qmul.ac.uk</u> to inform us of all other trial related information.
- PROTECTOR Collaborators meeting **Tuesday 17<sup>th</sup> September 2024** please save the date, more details to come!

Site	Recruitment
Barts Health NHS Trust	123
Guy's and St Thomas' NHS Foundation Trust	82
St George's University Hospitals NHS Foundation Trust	84
	76
Manchester University NHS Foundation Trust	48
Royal Surrey County Hospital NHS Foundation Trust	59
University College London Hospital Foundation Trust	47
Worcestershire Acute Hospital Trust	
Nottingham University Hospitals NHS Trust	51 42
Brighton and Sussex University Hospitals NHS Trust	
Belfast Health & Social Care Trust	49
University Hospitals Bristol NHS Foundation Trust	35
Cardiff and Vale NHS Trust	29
Liverpool Women's Hospital NHS Foundation Trust	36
Norfolk and Norwich University Hospitals	31
Portsmouth Hospitals NHS Trust	34
University Hospital Southampton NHS Foundation Trust	25
University Hospitals of Leicester NHS Trust	30
Ninewells Hospital, NHS Tayside	24
Royal Devon & Exeter NHS Foundation Trust	26
Royal Cornwall Hospitals NHS Trust	24
Northampton General Hospitals NHS Trust	19
Imperial College Healthcare NHS Trust	15
Aberdeen Royal Infirmary, NHS Grampian	20
Sandwell and West Birmingham Hospitals NHS Trust	28
East Lancashire Hospitals NHS Trust	21
North Tees and Hartlepool NHS Foundation Trust	11
County Durham and Darlington NHS Foundation Trust	10
Gateshead Health NHS Foundation Trust	13
Leeds Teaching Hospitals NHS Trust	22
East Kent Hospitals University NHS Foundation Trust	9
Ysbyty Gwynedd Hospital, Betsi Cadwaladr UHB	6
Maidstone and Tunbridge Wells NHS Trust	6
Newcastle upon Tyne Hospitals NHS Foundation Trust	7
NHS Greater Glasgow & Clyde	8
Royal Infirmary of Edinburgh, NHS Lothian	7
University Hospitals of Derby and Burton NHS Trust	6
Royal United Hospitals Bath NHS Foundation Trust	2
Northwick Park and St Mark's Hospitals	4
South Tyneside and Sunderland NHS Foundation Trust	1
South Tees Hospitals NHS Foundation Trust	2
Swansea Bay University Local Health Board	0
Cambridge University Hospitals NHS Trust	8



- The PROTECTOR study is open to BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, and PALB2 mutation carriers.
- Please notify us when a participant's surgery is scheduled or has happened.
- Please continue posting histopathology and cytology slides and blocks to the PROTECTOR team following local pathology review. Please notify us when slides are on the way and <u>ensure slides are sent in a timely manner. Please also ensure</u> <u>slides/blocks are pseudo-anonymized prior to sending.</u>
- You can contact the PROTECTOR team at <u>bci-protector@qmul.ac.uk</u>. Please do not send any patient identifiable information to this email. If you need to send us identifiable information, use our NHS email: protector.study@nhs.net.
- A reminder to <u>please complete baseline questionnaires in</u> <u>clinic</u> wherever possible and to contact patients whose <u>questionnaire is outstanding</u>.
- Completed Baseline questionnaires should be posted to the below address as soon as possible. Prepaid envelopes can be requested.

PROTECTOR Study Research Team Barts Cancer Institute, CECM Charterhouse Square London EC1M 6BQ

> Study website: protector.org.uk Twitter:@PROTECTOR\_QMUL

